{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:24:13Z","timestamp":1786991053838,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011501","name":"Qinghai Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.intimp.2024.111961","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T16:51:24Z","timestamp":1712854284000},"page":"111961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"133","author":[{"given":"Ping","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoshuang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengrong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaozhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuda","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5602-6048","authenticated-orcid":false,"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.111961_b0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2024.111961_b0010","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.111961_b0015","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2020.03.284","article-title":"ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)","volume":"31","author":"Paluch-Shimon","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2024.111961_b0020","unstructured":"Aya Y. Al-Kabariti MAA. Progress in the understanding of estrogen receptor alpha signaling in triple-negative breast cancer: Reactivation of silenced ER-\u03b1 and signaling through ER-\u03b136. doi: 10.1158\/1541-7786.MCR-23-0321\/3348383\/mcr-23-0321.pdf."},{"key":"10.1016\/j.intimp.2024.111961_b0025","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1245\/s10434-023-13714-x","article-title":"Neoadjuvant Immunotherapy in Early, triple-negative breast cancers: catching up with the rest","volume":"30","author":"Kim","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.intimp.2024.111961_b0030","first-page":"113","article-title":"Molecular biology mechanisms and emerging therapeutics of triple-negative breast cancer","volume":"17","author":"Zhang","year":"2023","journal-title":"Biologics"},{"key":"10.1016\/j.intimp.2024.111961_b0035","doi-asserted-by":"crossref","first-page":"434","DOI":"10.5732\/cjc.014.10122","article-title":"Immune checkpoint inhibitors in clinical trials","volume":"33","author":"Sharon","year":"2014","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.intimp.2024.111961_b0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.semcancer.2020.06.016","article-title":"Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer","volume":"79","author":"Gaynor","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.intimp.2024.111961_b0045","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2024.111961_b0050","article-title":"Immunotherapy-induced thyroid dysfunction: an updated review. The Egyptian","volume":"35","author":"Baraka","year":"2023","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.intimp.2024.111961_b0055","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40618-017-0778-8","article-title":"Thyroid dysfunctions secondary to cancer immunotherapy","volume":"41","author":"Chalan","year":"2018","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.intimp.2024.111961_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102352","article-title":"Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: a systematic review and meta-analysis","volume":"104","author":"Villacampa","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2024.111961_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117009","article-title":"Heterogeneity of breast cancer: The importance of interaction between different tumor cell populations","volume":"239","author":"Januskeviciene","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2024.111961_b0070","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-020-01295-y","article-title":"Atezolizumab (in Combination with Nab-Paclitaxel): a review in advanced triple-negative breast cancer","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2024.111961_b0075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.111961_b0080","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2024.111961_b0085","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1002\/jcb.28771","article-title":"Thyroid function following breast cancer chemotherapy: a systematic review","volume":"120","author":"Mortezaee","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.intimp.2024.111961_b0090","article-title":"statement: an updated guideline for reporting systematic reviews","volume":"2021","author":"Page","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2024.111961_b0095","doi-asserted-by":"crossref","unstructured":"JulianPTHiggins, Simon G Thompson, Jonathan J Deeks, et al. Measuring inconsistency in meta-analyses. 2003.","DOI":"10.1136\/bmj.327.7414.557"},{"key":"10.1016\/j.intimp.2024.111961_b0100","doi-asserted-by":"crossref","unstructured":"Matthias Egger, George Davey Smith, Martin Schneider, et al. Bias in meta-analysis detected by a simple, graphical test 1997.","DOI":"10.1136\/bmj.315.7109.629"},{"key":"10.1016\/j.intimp.2024.111961_b0105","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1186\/s12885-022-10363-3","article-title":"Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM\/2015-04 (PANGEA-Breast) study","volume":"22","author":"de la Cruz-Merino","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2024.111961_b0110","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1007\/s00262-023-03470-y","article-title":"Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer","volume":"72","author":"Egelston","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2024.111961_b0115","article-title":"Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer","volume":"9","author":"Fabi","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.intimp.2024.111961_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2023.01.001","article-title":"Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer \u2013 A single-arm phase II trial (NeoImmunoboost, AGO-B-041)","volume":"184","author":"Fasching","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2024.111961_b0125","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1038\/s41467-022-30569-0","article-title":"Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2024.111961_b0130","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2024.111961_b0135","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.111961_b0140","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 Trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2024.111961_b0145","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ejca.2021.02.028","article-title":"Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase \u2161 trial","volume":"148","author":"Perez-Garcia","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2024.111961_b0150","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1038\/s41591-022-02126-1","article-title":"Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial","volume":"28","author":"Rossevold","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2024.111961_b0155","doi-asserted-by":"crossref","unstructured":"S. Loibl MU, N. Burchardi. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer \u2013 clinical results and biomarker analysis of GeparNuevo study. 2019.","DOI":"10.1093\/annonc\/mdz158"},{"key":"10.1016\/j.intimp.2024.111961_b0160","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.111961_b0165","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.annonc.2020.01.072","article-title":"Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study","volume":"31","author":"Schmid","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2024.111961_b0170","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2020.3524","article-title":"Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor-positive, erbb2-negative metastatic breast cancer: a randomized clinical trial","volume":"6","author":"Tolaney","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2024.111961_b0175","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-20-4726","article-title":"Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): a phase ib\/ii study","volume":"27","author":"Tolaney","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.111961_b0180","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s43018-023-00542-x","article-title":"PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial","volume":"4","author":"Voorwerk","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.intimp.2024.111961_b0185","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10549-023-06929-9","article-title":"A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer","volume":"199","author":"Yam","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.intimp.2024.111961_b0190","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/BCTT.S442707","article-title":"Thyroid hormone changes correlate to combined breast cancer with primary thyroid cancer","volume":"16","author":"Jin","year":"2024","journal-title":"Breast Cancer Targets Ther."},{"key":"10.1016\/j.intimp.2024.111961_b0195","doi-asserted-by":"crossref","unstructured":"Bhardwaj PV and Abdou YG. The Evolving Landscape of Immune Checkpoint Inhibitors and Antibody Drug Conjugates in the Treatment of Early-Stage Breast Cancer. Oncologist 2023; 28: 832-844. 2023 20:42. doi: 10.1093\/oncolo\/oyad233.","DOI":"10.1093\/oncolo\/oyad233"},{"key":"10.1016\/j.intimp.2024.111961_b0200","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2021.09.013","article-title":"Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: a review","volume":"158","author":"Larroquette","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2024.111961_b0205","doi-asserted-by":"crossref","unstructured":"Profili NI, Castelli R, Gidaro A, et al. Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review. J Clin Med 2023; 12 2023. doi: 10.3390\/jcm12155161.","DOI":"10.3390\/jcm12155161"},{"key":"10.1016\/j.intimp.2024.111961_b0210","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1530\/EC-19-0473","article-title":"Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction","volume":"9","author":"Olsson-Brown","year":"2020","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.intimp.2024.111961_b0215","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/cncr.31200","article-title":"Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management","volume":"124","author":"Barroso-Sousa","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2024.111961_b0220","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.intimp.2024.111961_b0225","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","article-title":"Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1","volume":"96","author":"Mekki","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2024.111961_b0230","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.111961_b0235","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.111961_b0240","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3389\/fphar.2019.01671","article-title":"Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta-analysis of randomized controlled trials","volume":"10","author":"Da","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.111961_b0245","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1038\/s41467-021-23661-4","article-title":"Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade","volume":"12","author":"Khan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2024.111961_b0250","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1097\/CM9.0000000000002631","article-title":"Assessment of the safety and efficacy of combination chemotherapy and PD-1\/PD-L1 inhibitor treatment of breast cancer: a meta-analysis","volume":"136","author":"Qian","year":"2023","journal-title":"Chin. Med. J. (Engl)"},{"key":"10.1016\/j.intimp.2024.111961_b0255","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1186\/s12885-021-08997-w","article-title":"Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis","volume":"21","author":"Xin","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2024.111961_b0260","doi-asserted-by":"crossref","first-page":"1010279","DOI":"10.3389\/fendo.2022.1010279","article-title":"Thyroid-related adverse events induced by immune checkpoint inhibitors","volume":"13","author":"Chera","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692400479X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692400479X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T16:03:59Z","timestamp":1715616239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692400479X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":52,"alternative-id":["S156757692400479X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111961","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111961","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111961"}}